ES2412306T3 - Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio - Google Patents

Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio Download PDF

Info

Publication number
ES2412306T3
ES2412306T3 ES10012220T ES10012220T ES2412306T3 ES 2412306 T3 ES2412306 T3 ES 2412306T3 ES 10012220 T ES10012220 T ES 10012220T ES 10012220 T ES10012220 T ES 10012220T ES 2412306 T3 ES2412306 T3 ES 2412306T3
Authority
ES
Spain
Prior art keywords
hydroxybenzoyl
butanoate
chloro
amino
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10012220T
Other languages
English (en)
Inventor
Satej Bhandarkar
Shingai Majuru
Halina Leuchyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Application granted granted Critical
Publication of ES2412306T3 publication Critical patent/ES2412306T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

4-[(4-Cloro-2-hidroxibenzoil)amino]butanoato de sodio amorfo.
ES10012220T 2002-01-09 2003-01-09 Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio Expired - Lifetime ES2412306T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34761002P 2002-01-09 2002-01-09
US347610P 2002-01-09

Publications (1)

Publication Number Publication Date
ES2412306T3 true ES2412306T3 (es) 2013-07-11

Family

ID=23364463

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10012220T Expired - Lifetime ES2412306T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
ES03719286.1T Expired - Lifetime ES2664189T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03719286.1T Expired - Lifetime ES2664189T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio

Country Status (8)

Country Link
US (5) US7227033B2 (es)
EP (2) EP1469827B1 (es)
JP (1) JP4508646B2 (es)
AU (1) AU2003223158B2 (es)
CA (1) CA2471144C (es)
ES (2) ES2412306T3 (es)
HK (1) HK1153136A1 (es)
WO (1) WO2003057650A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469827B1 (en) * 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate
EP1592438B1 (en) * 2003-01-06 2014-02-26 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP2279732B1 (en) * 2004-05-14 2019-03-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20080132527A1 (en) 2004-05-19 2008-06-05 Emisphere Technologies, Inc. Compositions For Delivering Acyclovir
EP1750721A4 (en) 2004-05-19 2012-10-31 Emisphere Tech Inc TOPICAL FORMULATIONS BASED ON CROMOGLYCIC ACID
JP2008509145A (ja) * 2004-08-03 2008-03-27 エミスフィアー テクノロジーズ インコーポレイテッド 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
ES2535311T3 (es) 2004-12-29 2015-05-08 Emisphere Technologies, Inc. Formulaciones farmacéuticas de sales de galio
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
WO2011017346A2 (en) 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
DK2919804T3 (en) 2012-11-13 2018-05-14 Adocia Rapidly acting insulin formulation comprising a substituted anionic compound
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) * 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
US11922659B2 (en) * 2018-11-29 2024-03-05 Nec Solution Innovators, Ltd. Coordinate calculation apparatus, coordinate calculation method, and computer-readable recording medium
CN111925298B (zh) * 2020-09-02 2023-05-30 无锡紫杉药业有限公司 一种4-cnab及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5811856B2 (ja) * 1975-07-14 1983-03-04 中外製薬株式会社 ２ ４− ビス （２’ − アセトキシベンズアミド ） アンソクコウサンノ イケイケツシヨウノ セイゾウホウ
JPS5312417A (en) * 1976-07-20 1978-02-03 Sumitomo Chem Co Ltd Preparation of amorphous d rugs
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
CA1214170A (fr) 1981-06-16 1986-11-18 Patrick Choay Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2163444T3 (es) 1993-04-22 2002-02-01 Emisphere Tech Inc Composiciones y metodos para la administracion oral de farmacos.
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
JP3462895B2 (ja) * 1993-11-05 2003-11-05 三井化学株式会社 安息香酸誘導体の多価金属塩の製造方法
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE324907T1 (de) * 1997-02-07 2006-06-15 Emisphere Tech Inc Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
GB9808896D0 (en) 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
HU230799B1 (hu) * 1998-06-19 2018-06-28 Teijin Pharma Limited 2-(3-Ciano-4-izobutiloxifenil)-4-metil-5-tiazolkarbonsav polimorf módosulatai és eljárás ezek előállítására
AU5471199A (en) 1998-08-07 2000-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU3581300A (en) 1999-01-08 2000-07-24 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
DE19903275A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Lyophilisate mit verbesserter Rekonstituierbarkeit
DE60023841T2 (de) 1999-02-05 2006-05-24 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
AU3378100A (en) 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) * 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
GB9923934D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Plc Novel pharmaceutical
MXPA02004092A (es) 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
JP2001240581A (ja) * 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
AU2001281483A1 (en) 2000-03-21 2001-10-03 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
PT1299348E (pt) 2000-06-29 2008-05-12 Emisphere Tech Inc Compostos e composições para administração de agentes activos
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
EP1469827B1 (en) 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate

Also Published As

Publication number Publication date
US7893297B2 (en) 2011-02-22
AU2003223158A1 (en) 2003-07-24
CA2471144A1 (en) 2003-07-17
EP2272501A1 (en) 2011-01-12
HK1153136A1 (es) 2012-03-23
US7227033B2 (en) 2007-06-05
ES2664189T3 (es) 2018-04-18
EP1469827A2 (en) 2004-10-27
WO2003057650A2 (en) 2003-07-17
US20090010882A1 (en) 2009-01-08
EP1469827A4 (en) 2006-08-16
US7420085B2 (en) 2008-09-02
US7462368B2 (en) 2008-12-09
US20070161708A1 (en) 2007-07-12
JP2005520803A (ja) 2005-07-14
JP4508646B2 (ja) 2010-07-21
EP2272501B1 (en) 2013-03-20
AU2003223158B2 (en) 2008-01-17
US20080033204A1 (en) 2008-02-07
WO2003057650A3 (en) 2003-10-16
US20050272639A1 (en) 2005-12-08
US7208178B2 (en) 2007-04-24
CA2471144C (en) 2011-06-07
EP1469827B1 (en) 2017-12-27
US20050250852A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
ES2412306T3 (es) Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
IS2896B (is) Gerviaugasteinn
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
DE60300824D1 (de) Laserprojektionssystem
DK1947501T3 (da) Elektroaktivt kontaktlinsesystem
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
DE60238794D1 (de) Hydantoinderivate als MMP-Inhibitoren
DE60330227D1 (de) N3-alkylierte benzimidazol-derivate als mek-hemmer
ATE363463T1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
ITMI20020908A0 (it) Processo di preparazione di sodio alendronato
DE60311340D1 (de) Optischer Schalter
DE60331752D1 (de) Linsenhaltegestell
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
DK1347044T3 (da) Alkalisk protease
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE60232196D1 (de) Hochstabiles optisches mikroskop
DE60307196D1 (de) Optisches Abtastgerät
DE60336790D1 (de) Optisches Vermittlungssystem
DE60334211D1 (de) Objektivlinsentreiber
DE60304800D1 (de) Optischer Verstärker
UY3455Q (es) Dentifrico
DE60319891D1 (de) Optischer Verstärker
UY3461Q (es) Dentifrico
UY3462Q (es) Dentifrico